KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Shares Outstanding (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Shares Outstanding for 15 consecutive years, with $57.5 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 3.08% to $57.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $57.5 million through Dec 2025, up 3.08% year-over-year, with the annual reading at $57.5 million for FY2025, 3.08% up from the prior year.
  • Shares Outstanding for Q4 2025 was $57.5 million at Supernus Pharmaceuticals, up from $57.1 million in the prior quarter.
  • The five-year high for Shares Outstanding was $57.5 million in Q4 2025, with the low at $53.0 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $54.7 million, with a median of $54.6 million recorded in 2023.
  • The sharpest move saw Shares Outstanding grew 0.65% in 2022, then grew 3.44% in 2025.
  • Over 5 years, Shares Outstanding stood at $53.3 million in 2021, then increased by 1.87% to $54.3 million in 2022, then rose by 0.87% to $54.7 million in 2023, then increased by 1.86% to $55.7 million in 2024, then grew by 3.08% to $57.5 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $57.5 million, $57.1 million, and $56.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.